Tumor Eradication Article Published by Cance...(he Institute of Biochemistry andInstitut...),Health

Background

GL-ONC1 is a genetically stable oncolytic virus strain designed to locate, enter, colonize and destroy cancer cells without harming healthy tissues or organs. GL-ONC1 is based on vaccinia virus, which was used safely in millions of people as the vaccine against smallpox. Scientists at Genelux have modified this virus to increase its safety, tumor selectivity and anti-tumor activity without limiting its ability to replicate in cancer cells. GL-ONC1 also carries a unique fusion protein designed to provide non-invasive, real-time imaging capabilities, including tumor diagnosis and localization, microscopic analysis of tumor biopsies, cancer staging and follow-up treatment monitoring.

The safety and efficacy demonstrated in preclinical studies, along with vaccinia virus' well-documented safety record as a vaccine against smallpox, make GL-ONC1 a promising candidate for clinical trials. Clinical trials are expected to begin in the near future in the U.S. and Europe.

To read the abstract, visit: http://cancerres.aacrjournals.org/cgi/content/abstract/67/20/10038. For company information, visit: http://www.genelux.com.

Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements
'/>"/>